

CITATION REPORT

List of articles citing

The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis

DOI: 10.1007/s41669-020-00208-9

PharmacoEconomics - Open, 2020, 4, 669-677.

Source: <https://exaly.com/paper-pdf/77530628/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2	Budget impact of introducing tildrakizumab for psoriasis treatment in US. <i>Pharmacoeconomics & Outcomes News</i> , 2020 , 850, 8-8	0.1	
1	A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab. <i>Frontiers in Medicine</i> , 2021 , 8, 702776	4.9	4